(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of 38.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Day One Biopharmaceuticals's revenue in 2025 is $131,161,000.On average, 4 Wall Street analysts forecast DAWN's revenue for 2025 to be $15,200,339,474, with the lowest DAWN revenue forecast at $13,733,536,918, and the highest DAWN revenue forecast at $16,348,483,431. On average, 4 Wall Street analysts forecast DAWN's revenue for 2026 to be $23,362,215,938, with the lowest DAWN revenue forecast at $18,034,009,032, and the highest DAWN revenue forecast at $29,872,216,501.
In 2027, DAWN is forecast to generate $36,121,026,476 in revenue, with the lowest revenue forecast at $29,058,339,737 and the highest revenue forecast at $42,914,515,620.